You are here: Home » Companies » News
Business Standard

Dr Reddy's sees no impact from pricing regulator notice

NPPA has issued a show-cause notice to dozens of Indian and foreign drugmakers

Reuters  |  Mumbai 

Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said it expects no impact from a recent government notice that said the company is selling a high blood pressure drug that lacks the pricing regulator's approval. India's drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), issued a show-cause notice to dozens of Indian and foreign drugmakers, who according to them, were selling medicines without NPPA approval on pricing. Calling it a violation of the country's drugs law, the agency has sought an explanation from these ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Fri, May 19 2017. 17:15 IST
RECOMMENDED FOR YOU